Comparative Pharmacology
Head-to-head clinical analysis: TETRACYCLINE HYDROCHLORIDE versus TETREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TETRACYCLINE HYDROCHLORIDE versus TETREX.
TETRACYCLINE HYDROCHLORIDE vs TETREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
250-500 mg orally every 6 hours; or 500 mg to 1 g intravenously every 12 hours. Maximum oral dose: 4 g/day.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6-12 hours, not to exceed 4 g/day.
None Documented
None Documented
6-11 hours (prolonged to 57-120 hours in severe renal impairment; reduced in hepatic dysfunction; clinically relevant for dosing interval adjustments).
Terminal elimination half-life: 6-11 hours (mean 8 hours); prolonged in renal impairment (up to 20 hours).
Renal (60% unchanged via glomerular filtration), biliary (40% as active drug and metabolites, with enterohepatic recirculation; fecal elimination of unabsorbed drug).
Renal: 60% unchanged; biliary/fecal: 40% (mainly as glucuronide conjugates).
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic